Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.16 USD
Change Today 0.00 / 0.00%
Volume 0.0
AMAR On Other Exchanges
As of 8:10 PM 09/30/15 All times are local (Market data is delayed by at least 15 minutes).

amarillo biosciences inc (AMAR) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/16/14 - $0.76
52 Week Low
10/7/14 - $0.03
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

amarillo biosciences inc (AMAR) Related Businessweek News

No Related Businessweek News Found

amarillo biosciences inc (AMAR) Details

Amarillo Biosciences, Inc. engages in the development of biologics for the treatment of human and animal diseases. It owns or licenses four issued patents related to the low-dose oral delivery of interferon; and owns one issued patent on its dietary supplement, Maxisal. The company focuses on research for the treatment of influenza, hepatitis C, thrombocytopenia, and other indications using its natural human interferon alpha technology. Amarillo Biosciences, Inc. was founded in 1984 and is based in Amarillo, Texas.

3 Employees
Last Reported Date: 04/13/15
Founded in 1984

amarillo biosciences inc (AMAR) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $34.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $40.3K
Compensation as of Fiscal Year 2014.

amarillo biosciences inc (AMAR) Key Developments

Amarillo Biosciences Inc. Approves Amendments to Certificate of Formation and Bylaws

Amarillo Biosciences Inc. announced that at its special meeting held on July 10, 2015, shareholders approved the amendments to certificate of formation and bylaws.

Amarillo Biosciences Seeks Acquisitions

Amarillo Biosciences Inc. (OTCPK:AMAR) will look for joint venture opportunities with both private and public companies. Amarillo wishes to acquire the desired business through acquisition of the target company with the ownership percentage being anywhere from 20% to 100%. Joint-venturing with other companies will expedite growth and facilitate cash flow. Amarillo Biosciences may also raise funds through public offerings or private placements to acquire other foreign businesses and bring those companies into the U.S. public markets.

Amarillo Biosciences Inc. announced delayed annual 10-K filing

On 03/30/2015, Amarillo Biosciences Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMAR:US $0.16 USD 0.00

AMAR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AMAR.
View Industry Companies

Industry Analysis


Industry Average

Valuation AMAR Industry Range
Price/Earnings 0.7x
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow 1.1x
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMARILLO BIOSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at